Another classic set up that was been constantly rewarding investors long the risk reversal trade. Sector was been showing strength as you go down the cap scale. high and tight holds probably
If you haven`t bought ARDS before it went up 6X: Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week, I would consider purchasing the 4usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.45. If these options prove to be profitable prior to the earnings release,...
Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compatible with other drugs used for treating these conditions. Let's...
Buy idea on ARDX as you see on the chart after the breakout with force the vwap indicator and the resistance line by a big green candle with a large green volume. In other hand, we will have a reversal trend if we have the breakout with force the support line by a big red candle with a large red volume. Thanks!
ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally. On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00 This would be a 581% gain from the current level. Looking...
in at 4.03 lets see if this wild undisciplined bull runs
Looking at 1-hour chart hit resistant of 2.80 Pulling back Looking for an entry around 2.63 Potential Gap UP
Looking at 1-hour chart hit resistant of 2.80 Pulling back Looking for an entry around 2.63
Breakout above 2.2? and possible gap fill toward upside. The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy. FDA decision soon. Risk is traditional sell the news event.
NASDAQ:ARDX If it passes the bearish line it's time for a short position, and if it passes the bullish line it's time for the Long position, the price targets are on the chart.
ARDX A strong opportunity to buy a company's stock It may drop more, do not be afraid, it is a second opportunity to buy, I cannot determine the time when the company’s stock will rise, this is only known to the market maker, for this patience is important in trading a company’s stock I'm honored that you follow me on Tradingview ARDX
I think the ChART is about to explode north! Falling Wedge. Finding support on the descending diagonal inside the falling wedge. Bouncing inside channels on RSI & RSI divergence indicators.
With a bullish cross on the 50/200 on the 3 hr time frame. Above the 20 week. Continuation to the upside is in the works. Add here!
This trade is not actionable without volume confirmation, wedge breakout, and ofc a SET SL AND TP ALSO looking at GAP fill over $2.00+
This is why I took a small profit to make sure there was no large pullback. But it held the 20 WMA. Held RSI support. I'm back in...
Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only...
Ardelyx shares are trading higher after Ladenburg Thalmann upgraded the stock from Neutral to Buy and announced a $6 price target. Also, Citigroup maintained a Buy rating and raised its price target from $7 to $13. Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and...
MM's could shake out the paper hands. I'm taking small profits to see what happens next. Let's see if this extended hours falling wedge plays out.